Democritus University of Thrace (DUTH)
Η χορήγηση αλλοπουρινόλης ως αντιοξειδωτικού παράγοντα στην πρόληψη της μετα-αναστροφής ενδοσκοπικής χολαγγειο-παγκρεατογραφικής παγκρεατίτιτδας: κλινική μελέτη
Abstract
dc:descriptionIntroduction and aims of study: Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), occuring in 1%-2% of patients undergoing the procedure in most large series (0 - 40% in smaller series). The majority of patients have a mild course, with rapid resolution of symptoms and no sequalae, but acute necrotizing pancreatitis, although uncommon, is well recognized. Most attempts to prevent post-ERCP pancreatitis have been disappointing. Recently, clinical applications of protease inhibitors such as gabexate have shown that medical therapy may be successful in reducing pancreatic complications after ERCP, although the high cost and complexity of administration of these drugs limit their widespread use. There is some evidence, based on experimental models, that allopurinol may reduce postprocedural rates of hyperamylasemia, edema of the pancreas and true post-ERCP pancreatitis. Allopurinol, a specific xanthine oxidase inhibitor, prevents the generation of oxygen-derived free radicals and is expected to block the early events in the cascade leading to pancreatic injury. The aim of this prospective study was to determine the effect of prophylactic use of oral allopurinol on the incidence of post-ERCP pancreatitis. Material and Methods: 250 patients were randomized to receive either 600 mg allopurinol orally (Group A) or placebo (Group B), 2h prior to ERCP. Pancreatitis was considered to be present when there was upper abdominal pain with tenderness, need for narcotics analgesia, serum amylase more than three times the upper normal limit and prolonged hospitalization (>24h). Sex, age, sphincterotomy, pre-cut technique, pancreatic duct visualization, acinarization, presence of nephrogram and hospitalization were tested for significance as risk factors using multivariate analysis. Results: 125 patients were included in Group A and 118 patients were included in Group B. The incidence of pancreatitis (17.8% vs. 3.2%, p<0.05) was higher in the placebo group than in the allopourinol-pretreated group. The overall incidence of pancreatitis was 10,29%. Multivariate analysis showed that i) “Hospitalization” was a significant risk factor in favor of allopourinol group (x2=27,10;p<0,001) meaning that patients who receive allopourinol have a statistically less significant risk for prolonged hospitalization and ii) . women of placebo group had a ten fold odds ratio to suffer from pancreatitis than men in the same group becoming equal when they received allopourinol. Conclusions: Pretreatment with oral allopurinol decreases the incidence of post-Ercp pancreatitis, the length of hospitalization and reduces the risk of women to suffer from post-ERCP pancreatitis.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2004
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chatzis, Iosif
- Χατζής, Ιωσήφ
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/17463